HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Over 15 years' experience in both finance and healthcare, covering clinic operations, investment and equity research in both China and overseas.

Pre-IPO Bama Tea - The Business Model, the Challenges and the Outlook

Pre-IPO 52TOYS Development - The Business Model and the Concerns Behind

Pre-IPO Our United Corporation - The Business and the Concerns Behind

Pre-IPO Kayou - The Strength of Business Model and the Potential Risks Behind

Equity Capital Markets

Convalife Pharmaceuticals / Equity Capital Markets

<ul>
<li>Convalife’s business model is based on the Right-6D framework. Convalife aims to improve R&amp;D efficiency and shorten commercialization time by collaborating with industry partners for product commercialization after approval.</li>
<li>Hannaijia, CVL009, CVL218, CVL237 are facing different challenges in R&amp;D and commercialization. Our forecast for their peak sales is about RMB500-800 million, RMB300-500 million, RMB1-1.5 billion, RMB400-600 million, respectively.</li>
<li>Post-Money valuation after Series C2 Financing is RMB3.2 billion. A neutral scenario is valuation of RMB3.5-4 billion. Valuation upside potential depends on clinical and commercalization success of the core products.</li>
</ul>


Convalife’s business model is based on the Right-6D framework. Convalife aims to improve R&amp;D efficiency and shorten commercialization time by collaborating with industry partners for product commercialization after approval.
Hannaijia, CVL009, CVL218, CVL237 are facing different challenges in R&amp;D and commercialization. Our forecast for their peak sales is about RMB500-800 million, RMB300-500 million, RMB1-1.5 billion, RMB400-600 million, respectively.
Post-Money valuation after Series C2 Financing is RMB3.2 billion. A neutral scenario is valuation of RMB3.5-4 billion. Valuation upside potential depends on clinical and commercalization success of the core products.


Pre-IPO Convalife Pharmaceuticals - The Pipeline, the Concerns, and the Peak Sales